GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q3 FY25 results · Oct–Dec 2024
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹949.42 crore (up 17.9% from Q3 FY24) and net profit of ₹229.88 crore (up 402.8% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 949.42 | 805.26 | +17.9% | 1,010.77 | −6.1% |
| Other income | 35.07 | 28.11 | +24.8% | 34.54 | +1.5% |
| Total income | 984.49 | 833.37 | +18.1% | 1,045.31 | −5.8% |
| Profit before tax | 308.10 | 65.43 | +370.9% | 343.81 | −10.4% |
| Net profit for the period | 229.88 | 45.72 | +402.8% | 252.50 | −9.0% |
| EPS, basic (₹) | 13.57 | 9.89 | +37.2% | 14.67 | −7.5% |
| Net margin (%) | 24.2 | 5.7 | 25.0 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 946.36 | 804.98 | +17.6% | 1,000.05 | −5.4% |
| Other income | 35.06 | 28.34 | +23.7% | 32.19 | +8.9% |
| Total income | 981.42 | 833.32 | +17.8% | 1,032.24 | −4.9% |
| Profit before tax | 306.35 | 65.11 | +370.5% | 338.70 | −9.6% |
| Net profit for the period | 228.58 | 45.49 | +402.5% | 248.69 | −8.1% |
| EPS, basic (₹) | 13.49 | 9.88 | +36.5% | 14.45 | −6.6% |
| Net margin (%) | 24.2 | 5.7 | 24.9 |
Consolidated
- Filed with BSE
- 14 Feb 2025, 16:38 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Feb 2025, 16:38 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE